Molecular alterations are known to affect cancer occurrence and metastasis, which has led to the development of hormonal therapy that targets the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor type 2 (HER-2). The gene discussed is PGR; the disease is cancer.